Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Creighton University Novartis |
---|---|
Information provided by: | Creighton University |
ClinicalTrials.gov Identifier: | NCT00673218 |
If you are allergic to ragweed, and not taking certain medications, you will be asked to have blood drawn. We will perform experiments on your blood cells.
Condition | Intervention | Phase |
---|---|---|
Allergy |
Drug: Placebo Drug: Xolair |
Phase IV |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment |
Official Title: | The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils |
Estimated Enrollment: | 25 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Saline injection to match active
|
Drug: Placebo
Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
|
Treatment: Experimental
Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
|
Drug: Xolair
150 to 375 mg is administered SC every 2 or 4 weeks
|
Adult ragweed allergic subjects will have blood drawn. Basophils will be enriched and stimulated with allergen and controls. Supernatants from these stimulations will be assayed for cytokines and histamine.
Ages Eligible for Study: | 19 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Nebraska | |
Creighton University | |
Omaha, Nebraska, United States, 68131 |
Principal Investigator: | Robert G Townley, MD | Creighton University |
Responsible Party: | Creighton University ( Robert G. Townley, MD ) |
Study ID Numbers: | CIGE025AUS22 |
Study First Received: | March 30, 2008 |
Last Updated: | May 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00673218 History of Changes |
Health Authority: | United States: Institutional Review Board |
IL13 Cytokines Basophil stimulation |
Hypersensitivity Omalizumab |